ABSTRACT
OBJECTIVE: To establish a HPLC method for bufothionine in the skin of Bufo bufo gargarizans and Huachansu injection. METHOD: The samples were separated using a Lichrosob C18 column with CH3CN-H2O (10:90) as mobile phase. Flow rate was at 1.0 mL x min (-1) and the detection wavelength was at 225 nm. RESULT: The calibration curve of bufothionine was linear over the range of 0.0772-0.4632 microg and the average recovery was 99. 2%. The contents of bufothionine were fluctuated from 36.4-641.8 microg x g(-1) in the skin of Bufo bufo gargarizans and 22.47-33.16 microg x mL(-1) in Huachansu injection, respectively. CONCLUSION: The contents of bufothionine were greatly different between cultured and wild species. The method was suitable for the quality control of the skin of Bufo bufo gargarizans and its preparation.
Subject(s)
Materia Medica/chemistry , Phenothiazines/analysis , Skin/chemistry , Animals , Bufo bufo , China , Chromatography, High Pressure Liquid/instrumentation , Chromatography, High Pressure Liquid/methods , Injections , Materia Medica/administration & dosage , Materia Medica/isolation & purification , Quality Control , Reproducibility of ResultsABSTRACT
Although most cases of Reye's syndrome that were initially reported were fatal, the overall mortality is now 20 to 30 per cent, with an even lower rate in some series. Improvement is due to both increased awareness of this disease and advances in care for the critically ill child. A good outcome depends on recognition of the early manifestations of the syndrome and appropriate initial therapy based on the stage of the disease.
Subject(s)
Reye Syndrome , Adolescent , Barbiturates/administration & dosage , Catheterization , Child , Child, Preschool , Humans , Intubation, Intratracheal , Mannitol/therapeutic use , Pancuronium/therapeutic use , Pentobarbital/therapeutic use , Phenothiazines/adverse effects , Prognosis , Reye Syndrome/chemically induced , Reye Syndrome/complications , Reye Syndrome/diagnosis , Reye Syndrome/drug therapy , Reye Syndrome/etiology , Reye Syndrome/physiopathology , Reye Syndrome/therapy , Salicylates/adverse effectsSubject(s)
Emergency Service, Hospital , Physicians , Substance-Related Disorders/therapy , Alcoholism/therapy , Amphetamine/poisoning , Antipsychotic Agents/therapeutic use , Attitude of Health Personnel , Coma/therapy , Hallucinogens/poisoning , Hospitalization , Humans , Hypnotics and Sedatives/poisoning , Intensive Care Units , Opium/poisoning , Parasympatholytics/poisoning , Phenothiazines , Poisoning/therapy , Psychoses, Substance-Induced/drug therapy , Referral and Consultation , Substance Withdrawal Syndrome/therapySubject(s)
Poisoning/diagnosis , Poisons/administration & dosage , Age Factors , Amphetamine/poisoning , Amphetamines , Atropine Derivatives/poisoning , Barbiturates/poisoning , Charcoal/therapeutic use , Child , Child, Preschool , Gastric Lavage , Humans , Imipramine/poisoning , Infant , Ipecac/therapeutic use , Mushroom Poisoning/diagnosis , Opium/analogs & derivatives , Opium/poisoning , Organophosphate Poisoning , Phenothiazines/poisoning , Poisoning/drug therapy , Poisoning/pathology , Poisons/blood , Poisons/urine , Salicylates/poisoning , Tranquilizing Agents/poisoningSubject(s)
Adjuvants, Anesthesia/adverse effects , Anesthesia/adverse effects , Anesthetics/adverse effects , Addison Disease , Atropine/adverse effects , Barbiturates/adverse effects , Heart Function Tests , Humans , Injections, Intravenous , Opium/adverse effects , Phenothiazines/adverse effects , Porphyrias , Preanesthetic Medication/adverse effects , Scopolamine/adverse effects , Shock , Steroids/adverse effects , Vasoconstrictor Agents/adverse effectsSubject(s)
Hallucinogens/adverse effects , Psychoses, Substance-Induced/therapy , Substance-Related Disorders , Amphetamine/adverse effects , Cannabis/adverse effects , Chlorpromazine/therapeutic use , Drug Contamination , Humans , Mental Disorders/chemically induced , Opium/adverse effects , Phenothiazines/therapeutic use , Psychoses, Substance-Induced/diagnosis , Psychoses, Substance-Induced/drug therapy , PsychotherapySubject(s)
Employment , Occupational Medicine , Substance-Related Disorders/urine , Adult , Age Factors , Barbiturates/urine , Chromatography, Thin Layer , Ethnicity , Humans , Male , Mass Screening , Methadone/urine , Narcotics/urine , New York City , Opium/urine , Phenothiazines/urine , Physical Examination , Pilot Projects , Quinine/urine , Substance-Related Disorders/diagnosis , TelephoneSubject(s)
Chromatography, Ion Exchange , Substance-Related Disorders/urine , Amphetamine/urine , Barbiturates/urine , Carbon Isotopes , Chromatography, Thin Layer , Colorimetry , Fluorometry , Hallucinogens/urine , Histamine H1 Antagonists/urine , Humans , Hydrolysis , Indicators and Reagents , Ion Exchange Resins , Methods , Morphine/urine , Opium/urine , Phenothiazines/urine , Quinine/urine , Solvents , Tranquilizing Agents/urine , TritiumSubject(s)
Heroin , Substance-Related Disorders/epidemiology , Adolescent , Adult , Alcoholism , Amphetamine , Barbiturates , Cannabis , Cocaine , Hepatitis A/etiology , Hepatitis B/etiology , Humans , Lysergic Acid Diethylamide , Male , Middle Aged , Opium , Phenothiazines , Prisons , Psychotic Disorders/etiology , Sepsis/etiology , Smoking , United KingdomSubject(s)
Anesthetics/pharmacology , Intraocular Pressure/drug effects , Narcotics/pharmacology , Adult , Anesthesia, General , Barbiturates/pharmacology , Chlorpromazine/pharmacology , Female , Halothane/pharmacology , Humans , Male , Meprobamate/pharmacology , Middle Aged , Muscles/pharmacology , Opium/pharmacology , Phenothiazines/pharmacology , Succinylcholine/pharmacology , Tonometry, Ocular , Tranquilizing Agents/pharmacologySubject(s)
Poisoning , Acids/poisoning , Alcoholic Intoxication/therapy , Alkalies/poisoning , Antidotes/therapeutic use , Arsenic Poisoning , Atropa belladonna/poisoning , Barbiturates/poisoning , Benzene/poisoning , Carbon Monoxide Poisoning/therapy , Humans , India , Kerosene/poisoning , Mercury Poisoning/therapy , Opium/poisoning , Organophosphate Poisoning , Petroleum/poisoning , Phenothiazines/poisoning , Plants, Medicinal , Plants, Toxic , Poisoning/epidemiology , Poisoning/prevention & control , Poisoning/therapy , Salicylates/poisoning , Sulfonamides/poisoning , Tranquilizing Agents/poisoningSubject(s)
Analgesics/pharmacology , Anesthesia, Obstetrical , Fetus/drug effects , Analgesics/administration & dosage , Anesthetics, Local/pharmacology , Barbiturates/pharmacology , Chloral Hydrate/pharmacology , Diazepam/pharmacology , Female , Heroin/pharmacology , Humans , Injections, Intramuscular , Injections, Intravenous , Levallorphan/pharmacology , Maternal-Fetal Exchange , Meperidine/pharmacology , Morphine/pharmacology , Nalorphine/pharmacology , Opium/pharmacology , Pentazocine/pharmacology , Phenoperidine/pharmacology , Phenothiazines/pharmacology , Pregnancy , Scopolamine/pharmacologyABSTRACT
Se comunica una paciente de 44 años de edad que presentaba lesiones kaposiformes profusas, manifestación cutánea infrecuente del síndrome antifosfolípido. Se describen las características clínicas, los hallazgos de laboratorio, así como el tratamiento de esta enfermedad multisistémica